Lenvatinib Plus Pembrolizumab

12 Mar, 2021

Dr. Rajesh Bollam

Image
Lenvatinib plus pembrolizumab🧪associated w/ significantly longer progression-free survival and overall survival than sunitinib in Advanced Renal Cell Carcinoma‼️#KidneyCancer #RCC
⚡️⚡️ History in the making!
👏Lenvatinib+pembro vs Sun
✅PFS 20.9 mos vs 9.2 mos HR 0.39 p<0.001
✅OS HR:0.66 p=0.005
✅ORR 71% vs 36%, CR16%vs4%
👏Len+Eve vs Sun
✅PFS14.7 vs 9.2 mos HR0.65 p<0.001

Add a comment